This paper is only available as a PDF. To read, Please Download here.
This 6-week, multicenter, double-masked, placebo-controlled study compared the efficacy, tolerability, and safety of the recommended starting dose of oxaprozin (1200 mg/d) and a 1500-mg/d dose of nabumetone in the treatment of patients with moderate-to-severe osteoarthritis (OA) of the knee. A total of 347 patients with a mean age of 61.1 years were randomized to receive oxaprozin (116 patients), nobumetone (115 patients), or placebo (116 patients). Adults of either sex who were older than 18 years of age were eligible for entry into the study, if they had had OA of the knee for at least 6 months. Efficacy variables included knee pain on weight bearing, knee pain on motion, patients' and physicians' global assessments of OA, pain intensity as measured on a visual analog scale, and time to walk 50 feet as quickly as possible. Efficacy variables were assessed at baseline and at weeks 1, 2, 4, and 6. Between-group differences in efficacy variables were evident by week 1. Mean improvements were significantly greter with oxaprozin than with placebo for all efficacy variables at all time periods, except knee pain on motion at weeks 2 and 4 and time to walk 50 feet at weeks 1, 2, and 4. Mean improvements were significantly greater with nabumetone than with placebo for all efficacy variables at all time periods, except the following: knee pain on weight bearing at weeks 2, 4, and 6; knee pain on motion at weeks 2 and 4; patients' global assessment at week 4; and pain intensity as measured on a visual analog scale at weeks 2 and 4. There were, however, no significant differences between oxaprozin and nabumetone in any of these efficacy variables. Adverse events were reported by 83 (71.6%) patients who took exaprozin, by 80 (69.6%) patients who took nabumetone, and by 57 (49.1%) patients who took placebo. Adverse events were reported for significantly more patients taking oxaprozin or nabumetone than placebo. However, adverse events tended to be mild or moderate and rarely resulted in patients withdrawing from the study. Combined with the results of an earlier study, the results of this showed that a 1500-mg/d dose of nabumetone, which is higher than the recommended starting dose of 1000 mg/d, is required for efficacy equivalent to that of the recommended starting dose of oxaprozin, 1200 mg/d, in relieving the symptoms of OA. Thus nabumetone may require dosage titration from the recommended starting dose. Oxaprozin and nabumetone were found to have similar tolerability profiles, as shown by adverse-event monitoring and withdrawal rates, as well as clinically similar safety profiles, as demonstrated by physical examinations, hematologic and biochemical laboratory testing, hemoccult testing, and adverse-event monitoring and symptom assessment.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Therapeutics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Nonsteroidal anti-inflammatory drugs—differences and similarities.NEJM. 1991; 324: 1716-1725
- Actions and toxicity of nonsteroidal anti-inflammatory drugs.Curr Opin Rheumatol. 1995; 7: 159-166
- Nonsteroidal anti-inflammatory drugs.in: Kelley WN Harris Jr, ED Ruddy S Sledge CB 3rd ed. Textbook of Rheumatology. 1. WB Saunders Company, Philadelphia1989: 765-791
- Nonsteroidal antiinflammatory drugs and the gastrointestinal tract.Arthritis Rheum. 1995; 38: 5-18
- The efficacy and safety of oxaprozin versus piroxicam: Pooled results of double-blind trials in osteoarthritis.Drug Ther. 1993; (Suppl): 13-16
- A comparison of single daily doses of oxaprozin with multiple daily doses of ibuprofen for the treatment of rheumatoid arthritis.Semin Arthritis Rheum. 1986; 15 (Suppl 2): 54-58
- The efficacy and safety of single daily doses of oxaprozin in the treatment of rheumatoid arthritis: A comparison with aspirin.Semin Arthritis Rheum. 1986; 15 (Suppl 2): 47-53
- A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis.Curr Med Res Opin. 1985; 8: 689-695
- The efficacy and safety of single daily doses of oxaprozin in the treatment of osteoarthritis: A comparison with aspirin.Semin Arthritis Rheum. 1986; 15 (Suppl 2): 72-79
- Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis.Am J Med. 1987; 83 (Suppl 4B): 86-91
- Effect of nabumetone (BRL14777), a new anti-inflammatory drug, on human platelet reactivity ex-vivo: Comparison with naproxen.J Pharm Pharmacol. 1982; 34: 576-579
- Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults.Am J Med. 1987; 83 (Suppl 4B): 78-81
- Once-daily oxaprozin and piroxicam compared in osteoarthritis.Semin Arthritis Rheum. 1986; 15 (Suppl 2): 80-85
- a50th ed. Physicians' Desk Reference.®. Medical Economics Data Production Company, Montvale, NJ1996: 2314-2316
- b50th ed. Physicians' Desk Reference.®. Medical Economics Data Production Company, Montvale, NJ1996: 2395-2397
- Scott-Levin Physician Drug and Diagnosis Audit. 1995;
- Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee.Clin Ther. 1995; 17: 735-745
- Measurement of patient outcome in arthritis.Arthritis Rheum. 1980; 23: 137-145
- The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection.Med Care. 1992; 30: 473-483
- Towards a measure of patient-perceived handicap in rheumatic arthritis.Br J Rheumatol. 1994; 33: 378-382
© 1996 Published by Elsevier Inc.